Skip to main content
. 2015 Apr 27;5(4):e151. doi: 10.1038/nutd.2015.1

Figure 2.

Figure 2

Body weight gain and food intake. (a) Body weight development and (b) total weight gain during the CB1 inverse agonist treatment period. (c) Weekly food intake as a percentage of basal food intake during the habituation and treatment and (d) total cumulative food intake during the treatment period. Values are expressed as means±s.e.m., n=9–12. #P<0.05, ##P<0.01, ###P<0.001 comparing different treatments within one genotype. *P<0.05, ***P<0.001 comparing different genotypes within one treatment. Analyzed with (a, c) repeated measures ANOVA or (b, d) two-way ANOVA.